UCB announces U.S. FDA acceptance of new drug application and EMA MAA validation for zilucoplan for the treatment of generalized myasthenia gravis in adult patients
- Monday, November 14, 2022, 7:06
- Finance
- Add a comment
New drug application (NDA) for zilucoplan seeks approval for the treatment of generalized myasthenia gravis (gMG) in adult patients who are acetylcholine receptor antibody positive (AChR-Ab+) Acceptance by U.S. Food and Drug Administration (FDA) follows the recent European Medicines…
About the Author
adminasapcorp has written 41811 stories on this site.